Dr. Shah is a faculty member in heart failure, mechanical circulatory support (MCS), and cardiac transplantation at Inova Heart & Vascular. His research focuses on the use of clinical risk prediction models and biomarkers to improve outcomes of patients with advanced heart failure who receive MCS. Specifically, he engages in epidemiologic research to characterize risk of MCS-associated complications such as: device thrombosis, stroke, and gastrointestinal bleeding. His research team at Inova has also been using machine learning to continuously predict the risk of adverse events in ambulatory LVAD patients. In his translational lab, the Inova team performs assays to assess the risk of gastrointestinal bleeding and stroke using soluble protein biomarkers. He has recently completed a phase II, clinical trial to assess the safety of direct oral anticoagulants in LVAD patients. Finally, Dr. Shah and his team have focused clinical and translational research efforts to support reverse cardiac remodeling and myocardial recovery in MCS patients. His goal is to comprehensively phenotype clinical and translational features of MCS and recovery. Through this, his goal is to identify novel therapeutic and clinical management strategies to improve long-term patient outcomes